- Home
- SOPH vs RIGL Comparison
SOPH vs RIGL Comparison
Compare SOPH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- RIGL
- Stock Information
- Founded
- SOPH 2011
- RIGL 1996
- Country
- SOPH Switzerland
- RIGL United States
- Employees
- SOPH N/A
- RIGL N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- RIGL Health Care
- Exchange
- SOPH Nasdaq
- RIGL Nasdaq
- Market Cap
- SOPH 193.8M
- RIGL 335.5M
- IPO Year
- SOPH 2021
- RIGL 2000
- Fundamental
- Price
- SOPH $2.99
- RIGL $18.93
- Analyst Decision
- SOPH Buy
- RIGL Buy
- Analyst Count
- SOPH 1
- RIGL 5
- Target Price
- SOPH $7.00
- RIGL $36.40
- AVG Volume (30 Days)
- SOPH 171.1K
- RIGL 196.7K
- Earning Date
- SOPH 08-05-2025
- RIGL 08-05-2025
- Dividend Yield
- SOPH N/A
- RIGL N/A
- EPS Growth
- SOPH N/A
- RIGL N/A
- EPS
- SOPH N/A
- RIGL 2.08
- Revenue
- SOPH $67,173,000.00
- RIGL $203,077,000.00
- Revenue This Year
- SOPH $16.07
- RIGL $14.41
- Revenue Next Year
- SOPH $22.94
- RIGL $15.97
- P/E Ratio
- SOPH N/A
- RIGL $9.09
- Revenue Growth
- SOPH 4.66
- RIGL 70.16
- 52 Week Low
- SOPH $2.58
- RIGL $7.48
- 52 Week High
- SOPH $4.92
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- SOPH 52.64
- RIGL 44.97
- Support Level
- SOPH $2.99
- RIGL $18.24
- Resistance Level
- SOPH $3.40
- RIGL $19.35
- Average True Range (ATR)
- SOPH 0.25
- RIGL 0.90
- MACD
- SOPH 0.01
- RIGL -0.14
- Stochastic Oscillator
- SOPH 62.65
- RIGL 23.44
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.